Literature DB >> 33802597

Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma.

Ángela Marrugal1, Irene Ferrer1,2, David Gómez-Sánchez1,2, Álvaro Quintanal-Villalonga3, María Dolores Pastor4, Laura Ojeda1, Luis Paz-Ares1,2,5,6, Sonia Molina-Pinelo2,4.   

Abstract

Heat shock protein 90 (HSP90) plays an essential role in lung adenocarcinoma, acting as a key chaperone involved in the correct functioning of numerous highly relevant protein drivers of this disease. To this end, HSP90 inhibitors have emerged as promising therapeutic strategies, even though responses to them have been limited to date. Given the need to maximize treatment efficacy, the objective of this study was to use isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomic techniques to identify proteins in human lung adenocarcinoma cell lines whose basal abundances were correlated with response to HSP90 inhibitors (geldanamycin and radicicol derivatives). From the protein profiles identified according to response, the relationship between lactate dehydrogenase B (LDHB) and DNA topoisomerase 1 (TOP1) with respect to sensitivity and resistance, respectively, to geldanamycin derivatives is noteworthy. Likewise, rhotekin (RTKN) and decaprenyl diphosphate synthase subunit 2 (PDSS2) were correlated with sensitivity and resistance to radicicol derivatives. We also identified a relationship between resistance to HSP90 inhibition and the p53 pathway by glucose deprivation. In contrast, arginine biosynthesis was correlated with sensitivity to HSP90 inhibitors. Further study of these outcomes could enable the development of strategies to improve the clinical efficacy of HSP90 inhibition in patients with lung adenocarcinoma.

Entities:  

Keywords:  HSP90 inhibitors; lung adenocarcinoma; protein biomarkers predictive of response

Mesh:

Substances:

Year:  2021        PMID: 33802597      PMCID: PMC7962034          DOI: 10.3390/ijms22052538

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  63 in total

1.  SMARCA5 methylation and expression in gastric cancer.

Authors:  Carolina Oliveira Gigek; Luara Carolina Frias Lisboa; Mariana Ferreira Leal; Patricia Natalia Oliveira Silva; Eleonidas Moura Lima; André Salim Khayat; Paulo Pimentel Assumpção; Rommel Rodriguez Burbano; Marilia de Arruda Cardoso Smith
Journal:  Cancer Invest       Date:  2011-02       Impact factor: 2.176

Review 2.  Epigenetic alterations of the Wnt signaling pathway in cancer: a mini review.

Authors:  Ljiljana Serman; Tamara Nikuseva Martic; Alan Serman; Semir Vranic
Journal:  Bosn J Basic Med Sci       Date:  2014-11-12       Impact factor: 3.363

Review 3.  HSP90 and the chaperoning of cancer.

Authors:  Luke Whitesell; Susan L Lindquist
Journal:  Nat Rev Cancer       Date:  2005-10       Impact factor: 60.716

4.  Overexpression of SMARCA5 correlates with cell proliferation and migration in breast cancer.

Authors:  Quanxiu Jin; Xiaoyun Mao; Bo Li; Shu Guan; Fan Yao; Feng Jin
Journal:  Tumour Biol       Date:  2014-11-07

5.  Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.

Authors:  Mark L McCleland; Adam S Adler; Laura Deming; Ely Cosino; Leslie Lee; Elizabeth M Blackwood; Margaret Solon; Janet Tao; Li Li; David Shames; Erica Jackson; William F Forrest; Ron Firestein
Journal:  Clin Cancer Res       Date:  2012-12-06       Impact factor: 12.531

6.  Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

Authors:  Jim Sang; Jaime Acquaviva; Julie C Friedland; Donald L Smith; Manuel Sequeira; Chaohua Zhang; Qin Jiang; Liquan Xue; Christine M Lovly; John-Paul Jimenez; Alice T Shaw; Robert C Doebele; Suqin He; Richard C Bates; D Ross Camidge; Stephan W Morris; Iman El-Hariry; David A Proia
Journal:  Cancer Discov       Date:  2013-03-26       Impact factor: 39.397

Review 7.  HSP90 as a novel molecular target in non-small-cell lung cancer.

Authors:  Khashayar Esfahani; Victor Cohen
Journal:  Lung Cancer (Auckl)       Date:  2016-03-01

8.  Dynamic proteomics reveals bimodal protein dynamics of cancer cells in response to HSP90 inhibitor.

Authors:  Anat Zimmer; Shlomit Amar-Farkash; Tamar Danon; Uri Alon
Journal:  BMC Syst Biol       Date:  2017-03-07

Review 9.  Heat shock protein 90 targeting therapy: state of the art and future perspective.

Authors:  Manabu Tatokoro; Fumitaka Koga; Soichiro Yoshida; Kazunori Kihara
Journal:  EXCLI J       Date:  2015-01-06       Impact factor: 4.068

10.  Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry.

Authors:  Ángela Marrugal; Irene Ferrer; Maria Dolores Pastor; Laura Ojeda; Álvaro Quintanal-Villalonga; Amancio Carnero; Sonia Molina-Pinelo; Luis Paz-Ares
Journal:  Cells       Date:  2019-07-31       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.